MediMix Oncology
  • Home
  • Congresses
    • 2026
      • WCLC 2026
      • ESMO GI 2026
      • ASCO 2026
      • ELCC 2026
      • ENETS 2026
      • BSMO 50 YEARS
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • EADO 2025
  • STiP
  • Webinars
    • ESDO – GI Cancer – ASCO GI 2026
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
    • Cardiology
    • Rheumatology
    • Neurology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
ELCC 2024Lung Cancer

Updated safety data of AEGEAN study

4 April 2024

Dr László Urbán, pulmonologist from the Matrahaza University and Teaching Hospital, Matrahaza, Hungary presents updated safety data with ∼9 months additional study follow-up of the AEGEAN trial with perioperative durvalumab and neoadjuvant chemotherapy for resectable NSCLC patients.

With the educational support of:

You may also be interested in:

ELCC 2024 Daily highlight 1

Two good options for patients with stage III NSCLC

The remaining challenges with neo-adjuvant immunotherapy in early-stage NSCLC

Tags:

poster

Share Article

Website created by MediMix © 2026 - Privacy Policy

  • Home
  • Congresses
    • 2026
      • WCLC 2026
      • ESMO GI 2026
      • ASCO 2026
      • ELCC 2026
      • ENETS 2026
      • BSMO 50 YEARS
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • EADO 2025
  • STiP
  • Webinars
    • ESDO – GI Cancer – ASCO GI 2026
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
    • Cardiology
    • Rheumatology
    • Neurology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.